Home  |  Contact

Cellosaurus NK-92CI (CVCL_U271)

[Text version]

Cell line name NK-92CI
Synonyms NK-92 ci; NK92CI; NK-92 transfected with pCEP4-LTR-hIL2
Accession CVCL_U271
Resource Identification Initiative To cite this cell line use: NK-92CI (RRID:CVCL_U271)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6672.
Transfected with: HGNC; 6001; IL2.
Caution: NantKwest exclusively owns, controls and distributes this cell line.
Derived from sampling site: Peripheral blood. Cell type=Natural killer cell.
Disease Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2142 (NK-92)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): ATCC

Markers:
AmelogeninX,Y
CSF1PO11,12
D5S81812,13
D7S82010,11
D13S3179,12
D16S53911,12
TH016,9.3
TPOX8
vWA16,18

Run an STR similarity search on this cell line
Publications

PubMed=10365666; DOI=10.1089/10430349950018030
Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

Patent=US8034332
Klingemann H.-G.
Interleukin-secreting natural killer cell lines and methods of use.
Patent number US8034332, 11-Oct-2011

Cross-references
Cell line collections ATCC; CRL-2409 - Discontinued
Biological sample resources BioSample; SAMN03471837
Encyclopedic resources Wikidata; Q54930657
Entry history
Entry creation03-Feb-2014
Last entry update16-Dec-2021
Version number10